Evidence map›Paper›PMID 31692478›Full record

Observational studyInternational journal of chronic obstructive pulmonary disease2019

Dual versus triple therapy in patients hospitalized for COPD in France: a claims data study.

Faustine Dalon, Nicolas Roche, Manon Belhassen, Maëva Nolin, Hervé Pegliasco, Gaëtan Deslée, Bruno Housset, Philippe Devillier, Eric Van Ganse

Abstract readComparative StudyObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in International journal of chronic obstructive pulmonary disease, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Methods to assess COPD medications adherence in healthcare databases: a systematic review.European respiratory review : an official journal of the European Respiratory Society · 2023
    Pooled it
  2. Article
  3. Observational
  4. Rational use of inhaled corticosteroids for the treatment of COPD.NPJ primary care respiratory medicine · 2023
    Review
  5. Article
  6. Article
  7. Article
  8. Observational
  9. Beyond Dual Bronchodilation - Triple Therapy, When and Why.International journal of chronic obstructive pulmonary disease
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Faustine DalonPharmacoepidemiology Department, PELyon, Lyon, France.
Nicolas RocheRespiratory Medicine, Cochin Hospital, AP-HP and Paris Descartes University (EA2511), Sorbonne Paris Cité, Paris, France.
Manon BelhassenPharmacoepidemiology Department, PELyon, Lyon, France.
Maëva NolinPharmacoepidemiology Department, PELyon, Lyon, France.
Hervé PegliascoPulmonary Department, European Hospital, Marseille, France.
Gaëtan DesléePulmonary Department, INSERM U1250, Maison Blanche University Hospital, Reims, France.
Bruno HoussetPulmonary Department, CHI de Créteil, University Paris Est Créteil, Créteil, France.
Philippe DevillierDepartment of Airway Diseases, UPRES EA 220, Foch Hospital, Paris-Saclay University, Suresnes, France.
Eric Van GansePharmacoepidemiology Department, PELyon, Lyon, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purposes: Following a hospitalization for COPD, dual and triple therapies were compared in terms of persistence and relations with outcomes (exacerbations, health care resource use and costs). Methods: This was a historical observational database study. All patients aged ≥45 hospitalized for COPD between 2007 and 2015 were identified in a 1/97 Results: Of the 3,089 patients hospitalized for COPD, 1,538 (49.8%) received either dual or triple therapy in the 2 months following inclusion, and 1,500 (48.6%) had at least 30 days of follow-up available; 846 (27.4%) received dual therapy, and 654 (21.2%) received triple therapy. After matching, the number of exacerbations was 2.4 per year in the dual vs 2.3 in the triple group ( Conclusion: Following hospitalizations for COPD, patients on dual and triple therapy experienced recurrent exacerbations, limited adherence to therapies and high cost of care. Patients on triple therapy appeared more severe than those on dual therapy, as reflected by exacerbations and health care resource use.

Indexed as

Administrative Claims, HealthcareAdrenal Cortex HormonesAdrenergic beta-2 Receptor AgonistsAgedAged, 80 and overBronchodilator AgentsCost-Benefit AnalysisDatabases, FactualDisease ProgressionDrug CostsDrug Therapy, CombinationFemaleFranceHealth ResourcesHumansLungAdrenal Cortex HormonesAdrenergic beta-2 Receptor AgonistsBronchodilator AgentsMuscarinic AntagonistsCOPDexacerbationshealth care resource usepersistencetherapy

Identifiers

PMID31692478
PMCPMC6708389

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.